Most IV HTN meds ordered for patients with SBP <180 mm hg

Most IV HTN meds ordered for patients with SBP &amp;amp;#60;180 mm hg

(HealthDay)—Intravenous (IV) antihypertensives are often ordered and administered for patients with asymptomatic uncontrolled blood pressure (BP) levels that are not associated with immediate cardiovascular risk, according to a study published online Nov. 12 in the Journal of Hospital Medicine.

Melissa Lipari, Pharm.D., from Wayne State University in Detroit, and colleagues examined the frequency of prescribing and administering episodic IV antihypertensives and outcome in non-critically ill, hospitalized patients. Data were included for 246 patients with an episodic IV antihypertensive order.

Of the patients with an episodic IV antihypertensive order, 172 received 458 doses, with 48 percent receiving a single dose. The researchers found that more than 98 and 84.5 percent of episodic IV antihypertensive doses were administrated for systolic (SBP) of <200 mm Hg and <180 mm Hg, respectively. For patients receiving IV hydralazine and labetalol, there was a statistically significant decrease in average SBP and diastolic BP within six hours of administration. The oral inpatient medication regimen was adjusted in 52 percent of patients after administration of IV antihypertensives; compared to patients with no change to their oral regimens, these patients had a greater SBP reduction from admission to discharge.

"IV antihypertensive drugs are ordered and administered in with asymptomatic, uncontrolled BP for levels unassociated with substantive immediate cardiovascular risk, which may cause adverse effects," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

Journal information: Journal of Hospital Medicine

Copyright © 2015 HealthDay. All rights reserved.

Citation: Most IV HTN meds ordered for patients with SBP <180 mm hg (2015, November 20) retrieved 26 April 2024 from https://medicalxpress.com/news/2015-11-iv-htn-meds-patients-sbp.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Review examines inappropriate prescribing of IV fluids

8 shares

Feedback to editors